CN1212867A - Composition for prevention and treatment of cardio-cerebralvascular disease - Google Patents
Composition for prevention and treatment of cardio-cerebralvascular disease Download PDFInfo
- Publication number
- CN1212867A CN1212867A CN 97106631 CN97106631A CN1212867A CN 1212867 A CN1212867 A CN 1212867A CN 97106631 CN97106631 CN 97106631 CN 97106631 A CN97106631 A CN 97106631A CN 1212867 A CN1212867 A CN 1212867A
- Authority
- CN
- China
- Prior art keywords
- acid
- oil
- fatty acid
- compositions
- polyunsaturated fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A composition for preventing and curing cardiovascular and cerebrovascular diseases is prepared from the polyunsaturated fatty acids including at least eicosapentaenoic acid and gamma-linolenic acid, as well as one or more of docosahexaenoic acid, alpha-linolenic acid and palmitoleic acid, and the additive for preventing polyunsaturated fatty acid from being oxidized and improving its physiologic function.
Description
The present invention is to be the medicine or the health food of the control cardiovascular and cerebrovascular disease of main effective ingredient with polyunsaturated fatty acid.
Polyunsaturated fatty acid, particularly eicosapentaenoic acid, docosahexenoic acid, palmitoleic acid and gamma-Linolenic acid, the known effect that good control cardiovascular and cerebrovascular disease is arranged.The metabolite prostacyclin PGI of eicosapentaenoic acid and gamma-Linolenic acid
2And PGI
3Be anticoagulant, prevent thrombotic effective ingredient.Suppress thromboxane TXA
2Generation.Make the ratio of unbalance prostacyclin and thromboxane return to poised state.Make arteriosclerosis and thrombosis obtain effectively preventing.
The present invention seeks to disclose a kind of compositions of preventing and treating cardiovascular and cerebrovascular disease, its effect is better than single with above-mentioned various polyunsaturated fatty acid, thereby obtains a kind of control medicine and health food of efficient cardiovascular and cerebrovascular disease.
This compositions is made up of polyunsaturated fatty acid and the additive that is used for preventing the polyunsaturated fatty acid oxidation or strengthens its physiological function.Described polyunsaturated fatty acid has at least eicosapentaenoic acid and two kinds of compositions of gamma-Linolenic acid to exist simultaneously.Described polyunsaturated fatty acid except that eicosapentaenoic acid and gamma-Linolenic acid, can also have a kind of of following composition or several: docosahexenoic acid, alpha-linolenic acid, palmitoleic acid.Described additive can be a kind of of following composition or several: vitamin E, and tea polyphenols, solatene, fan's speed is fragrant, acetaminol, lecithin, taurine, Squalene, Litsea cubeba oil, Oleum Bulbus Allii.Hippophae rhamnoides seed oil.Described polyunsaturated fatty acid existence form is following animals and plants extract: fish oil, blackcurrant oil, Oleum Hippophae, Oleum Radix Arnebiae (Oleum Radix Lithospermi), borage oil, Radix Oenotherae erythrosepalae oil, microbial cells oil.Described polyunsaturated fatty acid effective ingredient can be fatty glyceride, fatty-acid ethyl ester, fatty acid or soap.Described additive.As being hard capsule, take simultaneously with the soft capsule that oily unsaturated fatty acid and oil-soluble additive thereof are made for non-oil soluble material.
Explanation of nouns:
Eicosapentaenoic acid, English is Eicosapentaenoic Acid, is abbreviated as EPA;
Docosahexenoic acid, English is Docosahexaenoic Acid, is abbreviated as DHA;
Gamma-Linolenic acid, English are Gamma Linolenic Acid, are abbreviated as GLA;
Alpha-linolenic acid, English are Alpha Linolenic Acid, are abbreviated as ALA;
Palmitoleic acid, English is Palmitoleic Acid, is abbreviated as POA;
Borage seed oil, English are Borage Seed Oil
Claims (6)
1. compositions of preventing and treating cardiovascular and cerebrovascular disease, be made up of polyunsaturated fatty acid and the additive that is used for preventing the polyunsaturated fatty acid oxidation or strengthens its physiological function, it is characterized in that: described polyunsaturated fatty acid has at least eicosapentaenoic acid and two kinds of compositions of gamma-Linolenic acid to exist simultaneously.
2. as the compositions of claim 1 described control cardiovascular and cerebrovascular disease, described polyunsaturated fatty acid except that eicosapentaenoic acid and gamma-Linolenic acid, can also have a kind of of following composition or several: docosahexenoic acid, alpha-linolenic acid, palmitoleic acid.
3. as the compositions of claim 1 described control cardiovascular and cerebrovascular disease, described additive can be a kind of of following composition or several: vitamin E, tea polyphenols, solatene; Herba Rosmarini Officinalis, acetaminol, lecithin, taurine; Squalene, Litsea cubeba oil, Oleum Bulbus Allii, hippophae rhamnoides seed oil.
4. as the compositions of claim 1 described control cardiovascular and cerebrovascular disease, described polyunsaturated fatty acid exists in following animals and plants extract: fish oil, blackcurrant oil, Oleum Hippophae, Oleum Radix Arnebiae (Oleum Radix Lithospermi), borage oil, Radix Oenotherae erythrosepalae oil, microbial cells oil.
5. as the compositions of claim 1 described control cardiovascular and cerebrovascular disease, described polyunsaturated fatty acid effective ingredient can be fatty glyceride, fatty-acid ethyl ester, fatty acid or soap.
6. as the compositions of claim 1 described control cardiovascular and cerebrovascular disease, described additive.As making hard capsule, take simultaneously with the soft capsule that oily unsaturated fatty acid and oil-soluble additive thereof are made for non-oil soluble material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97106631 CN1212867A (en) | 1997-09-29 | 1997-09-29 | Composition for prevention and treatment of cardio-cerebralvascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97106631 CN1212867A (en) | 1997-09-29 | 1997-09-29 | Composition for prevention and treatment of cardio-cerebralvascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1212867A true CN1212867A (en) | 1999-04-07 |
Family
ID=5168852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97106631 Pending CN1212867A (en) | 1997-09-29 | 1997-09-29 | Composition for prevention and treatment of cardio-cerebralvascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1212867A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002002105A1 (en) * | 2000-06-29 | 2002-01-10 | Laxdale Limited | Therapeutic combinations of fatty acids |
| CN100382797C (en) * | 2004-10-28 | 2008-04-23 | 昆明翔昊科技有限公司 | Confected product containing lutein and/or carotene linolenic acid, and its preparation method |
| CN101259121B (en) * | 2001-10-11 | 2011-04-06 | 巴利阿里群岛大学 | Use of hydroxyoleic acid and similar compounds in the production of medicaments |
| CN102416056A (en) * | 2011-11-19 | 2012-04-18 | 西北农林科技大学 | Compound nanoemulsion oral liquid for reducing blood fat and preparation method thereof |
| CN102805344A (en) * | 2012-08-04 | 2012-12-05 | 东莞市照燕生物科技有限公司 | Nutrition and health product for cardia-cerebrovascular diseases |
| CN104970360A (en) * | 2015-06-19 | 2015-10-14 | 贵州神奇药物研究院 | Health-care food for reducing blood lipid and preparation method of health-care food |
| US9925162B2 (en) | 2009-04-09 | 2018-03-27 | The Regents Of The University Of Colorado | Methods and compositions for inducing physiological hypertrophy |
-
1997
- 1997-09-29 CN CN 97106631 patent/CN1212867A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002002105A1 (en) * | 2000-06-29 | 2002-01-10 | Laxdale Limited | Therapeutic combinations of fatty acids |
| CN101259121B (en) * | 2001-10-11 | 2011-04-06 | 巴利阿里群岛大学 | Use of hydroxyoleic acid and similar compounds in the production of medicaments |
| CN100382797C (en) * | 2004-10-28 | 2008-04-23 | 昆明翔昊科技有限公司 | Confected product containing lutein and/or carotene linolenic acid, and its preparation method |
| US9925162B2 (en) | 2009-04-09 | 2018-03-27 | The Regents Of The University Of Colorado | Methods and compositions for inducing physiological hypertrophy |
| CN102416056A (en) * | 2011-11-19 | 2012-04-18 | 西北农林科技大学 | Compound nanoemulsion oral liquid for reducing blood fat and preparation method thereof |
| CN102805344A (en) * | 2012-08-04 | 2012-12-05 | 东莞市照燕生物科技有限公司 | Nutrition and health product for cardia-cerebrovascular diseases |
| CN104970360A (en) * | 2015-06-19 | 2015-10-14 | 贵州神奇药物研究院 | Health-care food for reducing blood lipid and preparation method of health-care food |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1121115T4 (en) | PUFA supplements | |
| US5532002A (en) | Gelatin pharmaceutical formulations | |
| US5738871A (en) | Pharmaceutical formulations | |
| US20110027443A1 (en) | Fat or oil composition containing oleic acid, linoleic acid, linolenic acid, and long-chain highly unsaturated fatty acid | |
| DE60000133T2 (en) | ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR SEASONS | |
| SE8405308L (en) | PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR THE PREPARATION OF THE SAME | |
| PT1310249E (en) | UTILIZATION OF POLY-INSATURATED FATTY ACIDS FOR PRIMARY PREVENTION OF SERIOUS CARDIOVASCULAR EVENTS | |
| TW200744463A (en) | Nutritional supplement containing long-chain polyunsaturated fatty acids | |
| AU2003238240A8 (en) | Analogues of lipid mediators derived from omega-3 pufas and methods of use | |
| CN1212867A (en) | Composition for prevention and treatment of cardio-cerebralvascular disease | |
| ATE306194T1 (en) | STABILIZED FAT MIXTURE, METHOD OF PRODUCING IT AND FOOD CONTAINING THE FAT | |
| JP2001346517A (en) | Edible fat and oil | |
| JP2000104092A (en) | Oil or fat composition for improving serum lipid | |
| EP0395569B1 (en) | A fatty product and a process for the production of same | |
| JPS6115648A (en) | Oil and fat food | |
| JP6777527B2 (en) | Oil composition | |
| JPS6115650A (en) | Oil-soluble liquid composition | |
| JP2022088159A (en) | Fat composition | |
| JPH06133707A (en) | Method for improving flavor of polyhydric unsaturated fatty acid-containing composition and food utilizing the same composition | |
| WO2003005831A1 (en) | Lamellar liquid crystals in viscous oil product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |